Company intelligence / Profile preview
Celltrion
Incheon, Incheon, South Koreacelltrionusa.com ↗
- Ownership
- Public · 068270
- Employees
- ~2000
- Development stage
- Commercial
01
Overview
Celltrion pioneered the world’s first monoclonal antibody biosimilar (“Remsima”) and has since become Korea’s largest exporter of biologics. The company has received regulatory approvals for numerous mAb-based therapies across autoimmune diseases and oncology. Recent FDA approvals include interchangeable designations for adalimumab (“Yuflyma”), omalizumab (“Omlyclo”), denosumab (“Osenvelt”, “Stoboclo”), tocilizumab (“Avtozma”), ustekinumab (“Steqeyma”) among others. Clinical data demonstrate comparable efficacy/safety to reference products with long-term maintenance results in inflammatory bowel disease.[1][2][3][4]
- Therapeutic areas
- GastroenterologyRheumatologyEndocrinologyDermatologyOncologyInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)BiosimilarsNovel biopharmaceuticals[1][3]Vaccines[3]
- Industry
- Biotech
02
Drug pipeline
38 assets37 more assets in the full pipeline.
Request access →03
Partnerships
Partnerships with major pharmaceutical companies for commercialization/distribution are common but specific partners are not listed in these sources.
Beyond the preview
Go deeper on Celltrion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celltrion.